The company hopes to build on this momentum in the coming quarters and continue to focus on our key brands to drive sustainable profitable growth
First and only next-generation protein-based adjuvanted COVID-19 booster approved in Europe
PIKA COVID-19 vaccine is currently in Phase 3, multi-country, multi-center clinical trial conducted at Southeast Asian and Middle East countries.
This is the third major regulatory milestone for the vaccine candidate following acceptance of regulatory submissions in Europe and Japan
Innovative Capsugel Enprotect capsule can simplify the manufacturing process to accelerate drug development and expedite first-in-human timelines
API platform to comprise of RA Chem Pharma, ZCL Chemicals and Avra Laboratories
Separate Phase 3 study evaluating 200 days of therapy with PREVYMIS in HSCT recipients at high risk of late clinically significant CMV infection recently completed, meeting its primary endpoint
He also highlighted the need for community awareness for continued implementation of the Covid Appropriate Behaviour (CAB) especially in view of the upcoming festival season
He is a seasoned business leader with a successful track record of over 26 years across local and area roles within the pharmaceutical industry
This recognition marks the third time in five years that Merck has been included on Fortune’s Change the World list.
Subscribe To Our Newsletter & Stay Updated
